Skip to content

Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity

Tumour Cell Response to Acute Aerobic Exercise in Breast Cancer Survivors: Modulatory Effects of Exercise Type and Intensity (TCReX) No: RSU/LSPA-PA-2024/1-0004 is Financed by the Investment of the European Union Recovery and Resilience Facility and the State Budget Within the Project "RSU Internal and RSU With LASE External Consolidation" No. 5.2.1.1.i.0/2/24/I/CFLA/005.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07439458
Acronym
TCReX
Enrollment
40
Registered
2026-02-27
Start date
2024-04-01
Completion date
2026-03-31
Last updated
2026-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Exercise, Breast Cancer Cell Lines, Breast Cancer Survivors, Healthy Women, Myokine Response

Brief summary

Cancer has emerged as a prominent cause of mortality in the 21st century, with breast cancer (BC) being the most diagnosed malignancy. Multidisciplinary cancer management has improved survival chances, but side effects and long-term consequences of treatments have significant implications for cancer survivors' health-related quality of life. Exercise is increasingly considered and used in cancer treatment and follow-up. However, studies demonstrating the biological mechanisms underlying the anticarcinogenic effects (ACE) of exercise are insufficient to justify the most appropriate physical activity for different clinical scenarios. Achieving scientific excellence in understanding the ACE of exercise in cancer management is critical to optimize treatment and enhance patients' quality of life.

Interventions

30 minutes of continuous exercise at 75% of VO2max, additionally 15 minutes of warm-up to reach specific workload.

30 minutes of continuous exercise at 45% of VO2max, additionally 15 minutes of warm-up to reach specific workload.

Sponsors

Riga Stradins University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
35 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

(intervention group): * Reproductive age (premenopausal); * Diagnosis of Stage II-III Triple-Negative Breast Cancer (TNBC) (negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)); * Timeframe of 3 to 9 months after completion of surgery, adjuvant chemotherapy, radiation therapy, and/or immunotherapy; * Physician-certified (cardiologist) physical fitness for exercise testing, supported by echocardiography (ECHO). Inclusion Criteria (control group): * Reproductive age (premenopausal); * No current or prior diagnosis of any type of cancer; * Matched by age, body constitution, and physical fitness to the breast cancer participant group.

Exclusion criteria

* Pregnancy; * Autoimmune diseases (e.g., thyroiditis, inflammatory bowel disease, atopic dermatitis, etc.); * Endocrine disorders (e.g., metabolic syndrome, diabetes); * Cardiovascular diseases; * Diagnosis of any other type of oncological disease; * Any condition for which physical activity is contraindicated (e.g., asthma, COPD, spinal disc herniation, severe iron deficiency anemia).

Design outcomes

Primary

MeasureTime frameDescription
Inhibition of Breast Cancer Cell Proliferation24 hours following cell exposure to serum collected at baseline (5 minutes pre-exercise) and immediately post-exercise (final minute of exercise).The inhibitory effect of exercise-conditioned serum (ECS) on the proliferation of breast cancer cell lines (MCF-7, SK-BR-3, and Hs578BT). Proliferation is measured as the percentage of viable cells after 24 hours of exposure to serum collected during exercise compared to baseline (pre-exercise) serum samples, using LIVE/DEAD fluorescence microscopy and FM CellHealth assays.
Changes in Serum Myokine ConcentrationsBlood samples were collected 5 minutes pre-exercise (baseline), 15, 30, and 45 minutes (final minute of exercise) at Day 8 (Visit 2) and Day 15 (Visit 3).Measurement of serum levels of six specific myokines (BDNF, SPARC, Oncostatin M, IL-6, FGF-21, and Decorin) known to exhibit anticarcinogenic effects. Concentrations will be determined using ELISA or xMAP technology.

Secondary

MeasureTime frameDescription
Correlation Between Body Composition and Myokine ResponseDay 1 (Visit 1): Baseline measurements (measured once during the initial screening). All measures were performed in the morning, from 8 a.m. to 12 p.m., after overnight fasting.Assessment of how body composition parameters - specifically fat mass, lean soft tissue mass, visceral fat, measured via Dual-Energy X-ray Absorptiometry (DEXA) - correlate with the magnitude of exercise-induced myokine fluctuations.

Countries

Latvia

Contacts

CONTACTDace Reihmane, PhD
Dace.Reihmane@rsu.lv+37126032249

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026